![](https://cdn.sanity.io/images/0vv8moc6/hcplive/ea4aa4bfe2255815686ef0a03947b5471e3ad4cc-936x944.png?fit=crop&auto=format)
Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months
The proposed denosumab biosimilar, SB16, demonstrated pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence, as well as equivalent efficacy, safety, and immunogenicity compared with the reference product among a cohort of postmenopausal women with …